{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:01:55Z","timestamp":1786978915612,"version":"build-2736575974"},"publisher-location":"Cham","reference-count":51,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031907616","type":"print"},{"value":"9783031907623","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-90762-3_5","type":"book-chapter","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T06:47:30Z","timestamp":1751525250000},"page":"93-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeted Treatment of Pediatric Craniopharyngioma: Lesson Learnt After 20-Year Experience with Intracystic Interferon Alpha"],"prefix":"10.1007","author":[{"given":"Paolo","family":"Frassanito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Massimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Tamburrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"5_CR1","first-page":"219","volume":"59","author":"G Pancucci","year":"2007","unstructured":"Pancucci G, Massimi L, Caldarelli M, et al. Pediatric craniopharyngioma: long-term results in 61 cases. Minerva Pediatr. 2007;59:219\u201331.","journal-title":"Minerva Pediatr"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/978-3-030-99166-1_4","volume":"45","author":"F Bianchi","year":"2022","unstructured":"Bianchi F, Benato A, Massimi L. Treatment of cystic Craniopharyngiomas: an update. Adv Tech Stand Neurosurg. 2022;45:139\u201376. https:\/\/doi.org\/10.1007\/978-3-030-99166-1_4.","journal-title":"Adv Tech Stand Neurosurg"},{"key":"5_CR3","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00381-023-06143-4","volume":"39","author":"L Massimi","year":"2023","unstructured":"Massimi L, Palombi D, Musarra A, et al. Adamantinomatous craniopharyngioma: evolution in the management. Childs Nerv Syst. 2023;39:2613\u201332. https:\/\/doi.org\/10.1007\/s00381-023-06143-4.","journal-title":"Childs Nerv Syst"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/s1130-1473(02)70576-9","volume":"13","author":"JF Al\u00e9n","year":"2002","unstructured":"Al\u00e9n JF, Boto GR, Lagares A, et al. Intratumoural bleomycin as a treatment for recurrent cystic craniopharyngioma. Case report and review of the literature. Neurocirugia (Astur). 2002;13:479\u201385.; discussion 485. https:\/\/doi.org\/10.1016\/s1130-1473(02)70576-9.","journal-title":"Neurocirugia (Astur)"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00381-010-1245-4","volume":"26","author":"BL Pettorini","year":"2010","unstructured":"Pettorini BL, Inzitari R, Massimi L, et al. The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Childs Nerv Syst. 2010;26:1779\u201384. https:\/\/doi.org\/10.1007\/s00381-010-1245-4.","journal-title":"Childs Nerv Syst"},{"key":"5_CR6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00381-005-1226-1","volume":"21","author":"S Cavalheiro","year":"2005","unstructured":"Cavalheiro S, Dastoli PA, Silva NS, et al. Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst. 2005;21:719\u201324. https:\/\/doi.org\/10.1007\/s00381-005-1226-1.","journal-title":"Childs Nerv Syst"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2010.1.FOCUS09310","volume":"28","author":"S Cavalheiro","year":"2010","unstructured":"Cavalheiro S, Di Rocco C, Valenzuela S, et al. Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus. 2010;28:E12. https:\/\/doi.org\/10.3171\/2010.1.FOCUS09310.","journal-title":"Neurosurg Focus"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1590\/s0004-282x2011000100011","volume":"69","author":"PA Dastoli","year":"2011","unstructured":"Dastoli PA, Nic\u00e1cio JM, Silva NS, et al. Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon. Arq Neuropsiquiatr. 2011;69:50\u20135. https:\/\/doi.org\/10.1590\/s0004-282x2011000100011.","journal-title":"Arq Neuropsiquiatr"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00381-007-0409-3","volume":"23","author":"DF Ierardi","year":"2007","unstructured":"Ierardi DF, Fernandes MJS, Silva IR, et al. Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas. Childs Nerv Syst. 2007;23:1041\u20136. https:\/\/doi.org\/10.1007\/s00381-007-0409-3.","journal-title":"Childs Nerv Syst"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3171\/jns.2000.92.2.0255","volume":"92","author":"RI Jakacki","year":"2000","unstructured":"Jakacki RI, Cohen BH, Jamison C, et al. Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas. J Neurosurg. 2000;92:255\u201360. https:\/\/doi.org\/10.3171\/jns.2000.92.2.0255.","journal-title":"J Neurosurg"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/neuonc\/nox056","volume":"19","author":"J-P Kilday","year":"2017","unstructured":"Kilday J-P, Caldarelli M, Massimi L, et al. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro-Oncology. 2017;19:1398\u2013407. https:\/\/doi.org\/10.1093\/neuonc\/nox056.","journal-title":"Neuro-Oncology"},{"key":"5_CR1001","doi-asserted-by":"publisher","unstructured":"Frassanito P, Thomale UW, Obersnel M, Romano A, Leblond P, Knerlich-Lukoschus F, Due-T\u00f8nnessen BJ, Thompson D, Di Rocco F; CPN Lyon 2024 Consensus Conference Group. The state of targeted therapeutic pharmacological approaches in pediatric neurosurgery: report from the European Society for Pediatric Neurosurgery (ESPN) Consensus Conference 2024.Childs Nerv Syst. 2025;41(1):149. https:\/\/doi.org\/10.1007\/s00381-025-06799-0.","DOI":"10.1007\/s00381-025-06799-0"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s11912-023-01471-9","volume":"25","author":"S Gabay","year":"2023","unstructured":"Gabay S, Merchant TE, Boop FA, et al. Shifting strategies in the treatment of pediatric Craniopharyngioma. Curr Oncol Rep. 2023;25:1497\u2013513. https:\/\/doi.org\/10.1007\/s11912-023-01471-9.","journal-title":"Curr Oncol Rep"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.17925\/EE.2021.17.2.121","volume":"17","author":"KI Alexandraki","year":"2021","unstructured":"Alexandraki KI, Xekouki P. Medical Therapy for Craniopharyngiomas. touchREV Endocrinol. 2021;17:121\u201332. https:\/\/doi.org\/10.17925\/EE.2021.17.2.121.","journal-title":"touchREV Endocrinol"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"1326595","DOI":"10.3389\/fonc.2023.1326595","volume":"13","author":"A Chen","year":"2023","unstructured":"Chen A, Ai M, Sun T. Advances in the treatment of Adamantinomatous craniopharyngioma: how to balance tumor control and quality of life in the current environment: a narrative review. Front Oncol. 2023;13:1326595. https:\/\/doi.org\/10.3389\/fonc.2023.1326595.","journal-title":"Front Oncol"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pediatrneurol.2024.10.016","volume":"162","author":"M Shatara","year":"2024","unstructured":"Shatara M, Abdelbaki MS. Pediatric Suprasellar tumors: unveiling the mysteries of Craniopharyngioma and germ cell tumors-insights from diagnosis to advanced therapeutics. Pediatr Neurol. 2024;162:55\u201368. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.10.016.","journal-title":"Pediatr Neurol"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00401-018-1830-2","volume":"135","author":"JR Apps","year":"2018","unstructured":"Apps JR, Carreno G, Gonzalez-Meljem JM, et al. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK\/ERK pathway as a novel therapeutic target. Acta Neuropathol. 2018;135:757\u201377. https:\/\/doi.org\/10.1007\/s00401-018-1830-2.","journal-title":"Acta Neuropathol"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"J-P Copp\u00e9","year":"2010","unstructured":"Copp\u00e9 J-P, Desprez P-Y, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99\u2013118. https:\/\/doi.org\/10.1146\/annurev-pathol-121808-102144.","journal-title":"Annu Rev Pathol"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00401-012-0957-9","volume":"124","author":"CL Andoniadou","year":"2012","unstructured":"Andoniadou CL, Gaston-Massuet C, Reddy R, et al. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol. 2012;124:259\u201371. https:\/\/doi.org\/10.1007\/s00401-012-0957-9.","journal-title":"Acta Neuropathol"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-015-0211-5","volume":"3","author":"JM Gump","year":"2015","unstructured":"Gump JM, Donson AM, Birks DK, et al. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun. 2015;3:30. https:\/\/doi.org\/10.1186\/s40478-015-0211-5.","journal-title":"Acta Neuropathol Commun"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1530\/ERC-18-0538","volume":"26","author":"G Carreno","year":"2019","unstructured":"Carreno G, Boult JKR, Apps J, et al. SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. Endocr Relat Cancer. 2019;26:355\u201366. https:\/\/doi.org\/10.1530\/ERC-18-0538.","journal-title":"Endocr Relat Cancer"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16:335\u201345. https:\/\/doi.org\/10.1038\/s41584-020-0419-z.","journal-title":"Nat Rev Rheumatol"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00381-020-04750-z","volume":"37","author":"C Desiderio","year":"2021","unstructured":"Desiderio C, Rossetti DV, Castagnola M, et al. Adamantinomatous craniopharyngioma: advances in proteomic research. Childs Nerv Syst. 2021;37:789\u201397. https:\/\/doi.org\/10.1007\/s00381-020-04750-z.","journal-title":"Childs Nerv Syst"},{"key":"5_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/bpa.12502","volume":"27","author":"L Massimi","year":"2017","unstructured":"Massimi L, Martelli C, Caldarelli M, et al. Proteomics in pediatric cystic craniopharyngioma. Brain Pathol. 2017;27:370\u20136. https:\/\/doi.org\/10.1111\/bpa.12502.","journal-title":"Brain Pathol"},{"key":"5_CR24","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1002\/elps.201300578","volume":"35","author":"C Martelli","year":"2014","unstructured":"Martelli C, Iavarone F, Vincenzoni F, et al. Proteomic characterization of pediatric craniopharyngioma intracystic fluid by LC-MS top-down\/bottom-up integrated approaches. Electrophoresis. 2014;35:2172\u201383. https:\/\/doi.org\/10.1002\/elps.201300578.","journal-title":"Electrophoresis"},{"key":"5_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00381-013-2069-9","volume":"29","author":"C Desiderio","year":"2013","unstructured":"Desiderio C, Martelli C, Rossetti DV, et al. Identification of thymosins \u03b24 and \u03b2 10 in paediatric craniopharyngioma cystic fluid. Childs Nerv Syst. 2013;29:951\u201360. https:\/\/doi.org\/10.1007\/s00381-013-2069-9.","journal-title":"Childs Nerv Syst"},{"key":"5_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1007\/s11033-024-10073-y","volume":"51","author":"Y Chen","year":"2024","unstructured":"Chen Y, Wang Z, Huang Q, et al. Differential proteomic profiles of exosomes in pediatric and adult adamantinomatous craniopharyngioma cyst fluid. Mol Biol Rep. 2024;51:1126. https:\/\/doi.org\/10.1007\/s11033-024-10073-y.","journal-title":"Mol Biol Rep"},{"key":"5_CR27","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","volume":"91","author":"JU Gutterman","year":"1994","unstructured":"Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA. 1994;91:1198\u2013205. https:\/\/doi.org\/10.1073\/pnas.91.4.1198.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ijc.2910510422","volume":"51","author":"I Saiki","year":"1992","unstructured":"Saiki I, Sato K, Yoo YC, et al. Inhibition of tumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Int J Cancer. 1992;51:641\u20135. https:\/\/doi.org\/10.1002\/ijc.2910510422.","journal-title":"Int J Cancer"},{"key":"5_CR29","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","volume":"89","author":"M Ferrantini","year":"2007","unstructured":"Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89:884\u201393. https:\/\/doi.org\/10.1016\/j.biochi.2007.04.006.","journal-title":"Biochimie"},{"key":"5_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/jnen\/nlx061","volume":"76","author":"AM Donson","year":"2017","unstructured":"Donson AM, Apps J, Griesinger AM, et al. Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human Adamantinomatous Craniopharyngioma. J Neuropathol Exp Neurol. 2017;76:779\u201388. https:\/\/doi.org\/10.1093\/jnen\/nlx061.","journal-title":"J Neuropathol Exp Neurol"},{"key":"5_CR31","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00381-017-3473-3","volume":"33","author":"W Zhu","year":"2017","unstructured":"Zhu W, Li X, He J, et al. A reformed surgical treatment modality for children with giant cystic craniopharyngioma. Childs Nerv Syst. 2017;33:1491\u2013500. https:\/\/doi.org\/10.1007\/s00381-017-3473-3.","journal-title":"Childs Nerv Syst"},{"key":"5_CR32","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/2019.10.FOCUS19705","volume":"48","author":"AC Hengartner","year":"2020","unstructured":"Hengartner AC, Prince E, Vijmasi T, Hankinson TC. Adamantinomatous craniopharyngioma: moving toward targeted therapies. Neurosurg Focus. 2020;48:E7. https:\/\/doi.org\/10.3171\/2019.10.FOCUS19705.","journal-title":"Neurosurg Focus"},{"key":"5_CR33","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s00381-020-04825-x","volume":"36","author":"L Jokonya","year":"2020","unstructured":"Jokonya L, Reid T, Kasambala M, et al. Antimicrobial effects of craniopharyngioma cystic fluid. Childs Nerv Syst. 2020;36:2641\u20136. https:\/\/doi.org\/10.1007\/s00381-020-04825-x.","journal-title":"Childs Nerv Syst"},{"key":"5_CR34","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3171\/2009.4.PEDS0978","volume":"4","author":"BL Pettorini","year":"2009","unstructured":"Pettorini BL, Tamburrini G, Massimi L, et al. Endoscopic transventricular positioning of intracystic catheter for treatment of craniopharyngioma. Technical note. J Neurosurg Pediatr. 2009;4:245\u20138. https:\/\/doi.org\/10.3171\/2009.4.PEDS0978.","journal-title":"J Neurosurg Pediatr"},{"key":"5_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fendo.2012.00039","volume":"3","author":"U Bartels","year":"2012","unstructured":"Bartels U, Laperriere N, Bouffet E, Drake J. Intracystic therapies for cystic craniopharyngioma in childhood. Front Endocrinol (Lausanne). 2012;3:39. https:\/\/doi.org\/10.3389\/fendo.2012.00039.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5_CR36","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/cncr.10547","volume":"94","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002;94:2675\u201380. https:\/\/doi.org\/10.1002\/cncr.10547.","journal-title":"Cancer"},{"key":"5_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3171\/2015.2.PEDS14656","volume":"16","author":"J Sharma","year":"2015","unstructured":"Sharma J, Bonfield CM, Singhal A, et al. Intracystic interferon-\u03b1 treatment leads to neurotoxicity in craniopharyngioma: case report. J Neurosurg Pediatr. 2015;16:301\u20134. https:\/\/doi.org\/10.3171\/2015.2.PEDS14656.","journal-title":"J Neurosurg Pediatr"},{"key":"5_CR38","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/MPH.0000000000000468","volume":"38","author":"LM Tiedemann","year":"2016","unstructured":"Tiedemann LM, Manley P, Smith ER, Dagi LR. Visual field loss in a case of recurrent cystic Craniopharyngioma during concomitant treatment with Pegylated interferon \u03b1-2b. J Pediatr Hematol Oncol. 2016;38:e26\u20138. https:\/\/doi.org\/10.1097\/MPH.0000000000000468.","journal-title":"J Pediatr Hematol Oncol"},{"key":"5_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00381-015-3005-y","volume":"32","author":"U Sandvik","year":"2016","unstructured":"Sandvik U, Grillner P, Holm S, Gustavsson B. Interferon or late effect of radiotherapy? Childs Nerv Syst. 2016;32:229\u201330. https:\/\/doi.org\/10.1007\/s00381-015-3005-y.","journal-title":"Childs Nerv Syst"},{"key":"5_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3171\/2012.9.PEDS12225","volume":"10","author":"JT Yeung","year":"2012","unstructured":"Yeung JT, Pollack IF, Panigrahy A, Jakacki RI. Pegylated interferon-\u03b1-2b for children with recurrent craniopharyngioma. J Neurosurg Pediatr. 2012;10:498\u2013503. https:\/\/doi.org\/10.3171\/2012.9.PEDS12225.","journal-title":"J Neurosurg Pediatr"},{"key":"5_CR41","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/neuonc\/noaa119","volume":"22","author":"S Goldman","year":"2020","unstructured":"Goldman S, Pollack IF, Jakacki RI, et al. Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a pediatric brain tumor consortium report. Neuro-Oncology. 2020;22:1696\u2013704. https:\/\/doi.org\/10.1093\/neuonc\/noaa119.","journal-title":"Neuro-Oncology"},{"key":"5_CR42","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00381-009-0978-4","volume":"25","author":"T Schubert","year":"2009","unstructured":"Schubert T, Trippel M, Tacke U, et al. Neurosurgical treatment strategies in childhood craniopharyngiomas: is less more? Childs Nerv Syst. 2009;25:1419\u201327. https:\/\/doi.org\/10.1007\/s00381-009-0978-4.","journal-title":"Childs Nerv Syst"},{"key":"5_CR43","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3171\/2011.6.JNS081451","volume":"116","author":"BM Hofmann","year":"2012","unstructured":"Hofmann BM, H\u00f6llig A, Strauss C, et al. Results after treatment of craniopharyngiomas: further experiences with 73 patients since 1997. J Neurosurg. 2012;116:373\u201384. https:\/\/doi.org\/10.3171\/2011.6.JNS081451.","journal-title":"J Neurosurg"},{"key":"5_CR44","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00381-012-1787-8","volume":"28","author":"C Mallucci","year":"2012","unstructured":"Mallucci C, Pizer B, Blair J, et al. Management of craniopharyngioma: the Liverpool experience following the introduction of the CCLG guidelines. Introducing a new risk assessment grading system. Childs Nerv Syst. 2012;28:1181\u201392. https:\/\/doi.org\/10.1007\/s00381-012-1787-8.","journal-title":"Childs Nerv Syst"},{"key":"5_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/EJE-11-0158","volume":"165","author":"HL M\u00fcller","year":"2011","unstructured":"M\u00fcller HL, Gebhardt U, Teske C, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol. 2011;165:17\u201324. https:\/\/doi.org\/10.1530\/EJE-11-0158.","journal-title":"Eur J Endocrinol"},{"key":"5_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3171\/ped.2007.106.1.3","volume":"106","author":"S Puget","year":"2007","unstructured":"Puget S, Garnett M, Wray A, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg. 2007;106:3\u201312. https:\/\/doi.org\/10.3171\/ped.2007.106.1.3.","journal-title":"J Neurosurg"},{"key":"5_CR47","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis MA, Legault G, Fisher MJ, et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology. 2014;16:1408\u201316. https:\/\/doi.org\/10.1093\/neuonc\/nou059.","journal-title":"Neuro-Oncology"},{"key":"5_CR48","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.3171\/2010.1.FOCUS09300","volume":"28","author":"BL Pettorini","year":"2010","unstructured":"Pettorini BL, Frassanito P, Caldarelli M, et al. Molecular pathogenesis of craniopharyngioma: switching from a surgical approach to a biological one. Neurosurg Focus. 2010;28:E1. https:\/\/doi.org\/10.3171\/2010.1.FOCUS09300.","journal-title":"Neurosurg Focus"},{"key":"5_CR49","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/nan.12226","volume":"41","author":"JP Martinez-Barbera","year":"2015","unstructured":"Martinez-Barbera JP. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma. Neuropathol Appl Neurobiol. 2015;41:721\u201332. https:\/\/doi.org\/10.1111\/nan.12226.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"5_CR50","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3171\/2017.1.JNS162232","volume":"128","author":"SB Omay","year":"2018","unstructured":"Omay SB, Chen Y-N, Almeida JP, et al. Do craniopharyngioma molecular signatures correlate with clinical characteristics? J Neurosurg. 2018;128:1473\u20138. https:\/\/doi.org\/10.3171\/2017.1.JNS162232.","journal-title":"J Neurosurg"}],"container-title":["Advances and Technical Standards in Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-90762-3_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:28:50Z","timestamp":1780720130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-90762-3_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031907616","9783031907623"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-90762-3_5","relation":{},"ISSN":["0095-4829","1869-9189"],"issn-type":[{"value":"0095-4829","type":"print"},{"value":"1869-9189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"4 July 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}